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Abstract
Purpose The aim of this study is to provide a comprehensive
overview of the outcomes of marketing authorisation applica-
tions via the mutual recognition and decentralised procedures
(MRP/DCP) and assess determinants of licensing failure dur-
ing CMDh referral procedures.
Methods All MRP/DCP procedures to the Co-ordination
group for Mutual recognition and Decentralised procedures–
human (CMDh) during the period from January 2006 to De-
cember 2013 were analysed. Reasons for starting referral pro-
cedures were scored. In addition, a survey under pharmaceu-
tical companies was performed to estimate the frequency of
licensing failure prior to CMDh referrals.
Results During the study period, 10392 MRP/DCP procedures
were finalized. Three hundred seventy-seven (3.6%) resulted in
a referral procedure, of which 70 (19 %) resulted in licensing
failure, defined as refusal or withdrawal of the application. The
frequency of CMDh referrals decreased from 14.5% in 2006 to
1.6 % in 2013. Of all referrals, 272 (72 %) were resolved
through consensus within the CMDh, the remaining 105
(28 %) were resolved at the level of the CHMP. Most referrals
were started because of objections raised about the clinical de-
velopment program. Study design issues and objections about
the demonstration of equivalence were most likely to result in
licensing failure. An estimated 11 % of all MRP/DCP proce-
dures resulted in licensing failure prior to CMDh referral.
Conclusion Whereas the absolute number of MRP/DCP pro-
cedures resulting in a referral has reduced substantially over
the past years, no specific time trend could be observed re-
garding the frequency of referrals resulting in licensing failure.
Increased knowledge at the level of companies and regulators
has reduced the frequency of late-stage failure of marketing
applications via the MRP/DCP.
Keywords MRP/DCP procedure . CMDh referrals .
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Introduction
Several regulatory pathways exist to authorise medicines in
the European Union (EU). The centralised procedure was in-
troduced in European legislation in 1993 and came into oper-
ation in 1995 [1, 2]. It results in a single marketing authorisa-
tion (MA) that is valid throughout the EU. The centralised
procedure is mandatory for marketing authorisation applica-
tions (MAAs) of new active substances for the treatment of
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HIV/AIDS, cancer, diabetes, neurodegenerative diseases,
auto-immune and other immune dysfunctions, and viral dis-
eases, all biologicals, advanced therapies, and orphan prod-
ucts. Applications for multiple Member States for products
that do not fall within the mandatory scope of the centralised
procedure must follow the mutual recognition procedure
(MRP) or the decentralised procedure (DCP). In terms of vol-
ume, MRP and DCP procedures outnumber the centralised
procedure and considerable resources are spent by both MA
holders and national competent authorities on MAAs via the
MRP/DCP procedures. When MAAs result in licensing fail-
ure—defined as those procedures that did not result in a
MA—this leads to wasted resources, especially if this con-
cerns preventable, late-stage failures. Whereas reasons for li-
censing failure for products authorised via the centralised pro-
cedure has received considerable attention, little is known
about MAAs via the MRP/DCP procedure [3, 4].
Since January 1, 1998, theMRP is mandatory for any prod-
uct that is to be marketed in multiple Member States, when a
MA exists anywhere in the EU [5]. During the MRP, an appli-
cant informs the ReferenceMember State (RMS) that it aims to
market a product in multiple countries and requests these other
countries, the so-called concerned member states (CMSs), to
recognise the MA granted by the RMS. The RMS circulates
the assessment report, including the approved summary of
product characteristics (SmPC), labelling and package leaflet.
If the CMSs agree with the assessment of the RMS, they
should recognise the decision within 90 days after receipt of
these documents by granting a national MA (Fig. S1) [6].
The DCP was introduced into European legislation in 2004
and should be followed when a MA is applied for in multiple
Member States at once [7]. Like the MRP, the DCP is also
based on recognition of a first assessment performed by a
RMS, but there is no preexisting MA. For both MRP and
DCP procedures, a positive outcome will result in harmonised
national MAs, granted by the respective national competent
authorities. After a positive outcome of the MRP/DCP proce-
dure (i.e. all CMSs agree to grant the MA), the procedure is
closed and a national MA should be granted within 30 days,
provided that well-translated documents are provided within
5 days after closing the procedure.
Member States can refuse to recognise the assessment of
the RMS, but only on grounds of a ‘potential serious risk to
public health’ (PSRPH). A PSRPH is defined as ‘a situation
where there is a significant probability that a serious hazard
resulting from a human medicinal product in the context of its
proposed use will affect public health’ [8]. Despite the devel-
opment of guidance, uncertainty remains about what qualifies
as a PSRPH [9]. If disagreement on the PSRPH cannot be
resolved by the RMS and the CMSs, the issue is referred to
the Co-ordination group for mutual recognition and
decentralised procedures–human (CMDh), through a so-
called Article 29(1) procedure. The CMDh works by
achieving consensus between the Member States. If it does
not achieve consensus to approve or refuse the MAA within
60 days, the case is referred to the Committee for Medicinal
Products for Human Use (CHMP) through an Article 29(4)
procedure who will adopt an opinion that will result in a bind-
ing decision from the European Commission [10].
Limited data are currently available on the outcomes of
MAAs via the MRP/DCP procedure. Furthermore, data on
licensing failure prior to MRP/DCP procedures are not avail-
able from publicly accessible sources. Therefore, the current
study aims to assess the efficiency of the MRP/DCP procedure
by providing a comprehensive overview of the outcomes with
these regulatory pathways. To do so, we have investigated fre-
quencies and determinants for CMDh referral procedures, as
well as reasons for licensing failure during the MRP/DCP.
Three objectives were formulated. The first objective was to
determine the frequency of CMDh referrals. The second objec-
tive was to assess the association of objections raised as PSRPH
and other determinants with licensing failure during CMDh
referrals. The third objective of this study was to determine
the frequency of licensing failure of MAAs via the MRP/DCP
prior to the initiation of a CMDh referral procedure.
Methods
Data were obtained from different sources. The total number of
MRP/DCP procedures finalised between January 2006 to De-
cember 2013 and all data relating to Article 29(1) procedures,
including procedure type (i.e. DCP or MRP), legal basis (see
Table S1) and prescription status, were obtained from statistics
and reports available from the CMDh website [11]. Additional
data on individual products, including pharmaceutical form
and legal status were retrieved from public assessment reports
that were obtained via the Mutual Recognition Product Index
[12]. Article 29(4) commission decision reports were obtained
from the European Commission pharmaceuticals community
register [13]. Our analysis was limited to initial MAAs; renew-
al procedures and type II variations were excluded.
A scoring system was developed to categorise objections
raised during the CMDh procedure (see Table S2 of the Sup-
plementary information). Two researchers (HE and JL) inde-
pendently scored the objections; disagreement was resolved
by consensus. Multiple objections were scored as ‘Multiple
objections from different categories’, unless the issues con-
cerned the same category. Licensing failure was defined as a
MAA procedure that did not result in a MA and included
negative results at the level of the CMDh, a negative European
Commission decisions, or withdrawals by the applicant.
MAAs via the MRP/DCP may also result in licensing fail-
ure prior to the start of a CMDh referral. When an MAA is
withdrawn before day 90 of the MRP (including the
preexisting MAs) or day 120 of the DCP procedure, the
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information will not be reported on the CMDh website and
was thus not available for our study. Therefore, a survey was
conducted under 58 member companies of the European Fed-
eration of Pharmaceutical Industries and Associations
(EFPIA) and the Association of the European Self-
Medication Industry (AESGP) to estimate the frequency of
licensing failure during the early phase of the MRP/DCP pro-
cedure. The European Generic Association (EGA) declined
the invitation to participate in the survey. The survey also
included questions on the consequences of PSRPHs raised
during the MRP/DCP.
All data were entered into a database, and descriptive sta-
tistics were obtained using IBM SPSS statistics version 20.0.0
(IBM Corporation, 2011). Significance for numerical vari-
ables was tested using Mann-Whitney U test (two-sided α<
5 %).
Results
Frequency of referral procedures
A total of 10,392MRP/DCP procedures were finalised during
the study period, 2822 MRP and 7570 DCP procedures
(Table 1). Generic applications accounted for 78 % of the
procedures and hybrid procedures for 10%. Full dossiers were
provided for 6 % of the applications, bibliographic applica-
tions accounted for 4 % and the remaining 2 % concerned
other applications (see Table S1). Most MAAs concerned
products that were authorised as prescription-only in the
RMS.
While MRP procedures predominated in 2006 and 2007,
from 2008, DCP procedures accounted for the majority of the
MAAs. During the study period, 377 (3.6 %) CMDh referral
procedures were started. During the first years after the
introduction of the DCP, more procedures resulted in a refer-
ral, compared to more recent years (Fig. 1). For the combined
MRP/DCP procedures, the frequency of CMDh referrals de-
clined from 14.5% in 2006 to 1.6 % in 2013.MRP procedures
were nearly five times more likely to result in a referral than
DCP procedures (Table 1). MAAs based on a full dossier and
on bibliographic data were more likely to result in a referral
compared to generic applications. No difference in the fre-
quency of CMDh referrals was observed for prescription ver-
sus nonprescription medicines.
Assessment of determinants of licensing failure
during the CMDh referrals
Of the 377 CMDh referrals, consensus was found within the
CMDh for 272 (72 %) referrals, leading to a positive opinion
for 239 (63 %) MAAs and licensing failure for 33 (9 %)
MAAs. Article 29(4) procedures (CHMP arbitrations) were
started for 105 (28 %) MAAs. Of these, 37 (10 %) ended in
a refusal and 68 (18 %) resulted in a positive recommendation
from the CHMP. So, overall, 70 (19 %) MAAs resulted in a
licensing failure. Two illustrative cases that were referred to
the CMDh are presented in supplementary Box 1. The major-
ity of PSRPH leading to a CMDh referral procedure were
related to the clinical phase (Table 2). PSRPHs concerning
the main category benefit-risk concerns accounted for most
CMDh referrals. PSRPHs related to the design of the clinical
studies and the demonstration of therapeutic equivalence and
bioequivalence were more likely to result in a licensing failure
during the referral procedure, than referrals started because of
benefit/risk concerns, quality or regulatory/procedural objec-
tions. For 88 referrals, multiple objections from different cat-
egories were raised (see Table S4 for more detailed informa-
tion on the combinations). The number of CMDh referrals was
small, especially in the second half of the study period. No
Table 1 Total number of marketing authorisation applications and CMDh referrals
Total, n Referrals, n Percent Risk ratio (95 % CI)
Procedure type DCP 7570 135 1.8 % Ref
MRP 2822 242 8.6 % 4.8 (3.9–5.9)
Perioda 2010–2013 6140 70 1.1 % Ref
2006–2009 4245 307 7.2 % 6.3 (4.9–8.2)
Prescription status (in RMS) Prescription only 9890 356 3.6 % Ref
Non-prescription 502 21 4.2 % 1.2 (0.8–1.8)
Legal basis* Art. 10.1—Generic 8120 248 3.1 % Ref
Art. 10.3—Hybrid 1010 29 2.9 % 0.9 (0.6–1.4)
Art. 8.3—Full dossier 600 63 10.5 % 3.4 (2.6–4.5)
Art. 10a—Well-established use (bibliographic) 439 29 6.6 % 2.2 (1.5–3.1)
Art 10b—Fixed combination 147 8 5.4 % 1.8 (0.9–3.5)
Other 56 0 0 % NA
aTotal numbers differ from procedure type and prescription status categories due to missing data
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time trends could be observed in terms of relative frequency of
the categories of PSRPH leading to CMDh referral. (Fig. 2
and supplementary Table S3).
No association was observed between licensing failure and
active substance type, administration route, prescription status
or MRP vs. DCP application during the referral procedure
(Table 3). Referrals of MAAs based on a full dossier (Article
8.3) were less likely to result in licensing failure. Cardiovascular
products and nervous system products were the two product
classes most frequently included in CMDh referrals. Antineo-
plastic and immunomodulating agents and genitourinary
system and sex hormones were less likely to result in licensing
failure when compared to cardiovascular agents.
The Netherlands, Germany, Denmark, the UK and Sweden
together acted as RMS for 78 % of all referrals. Procedures in
which the Netherlands or Sweden were RMS, were less likely
to result in licensing failure, whereas procedures where Den-
mark was the RMS more often resulted in licensing failure,
when compared to all other Member States. Per procedure, a
median of 8 (IQR 4–12) CMSs were involved. Procedures that
resulted in licensing failure involved fewer CMSs (5.5; IQR 1–
9) than procedures with a positive outcome (8; IQR 4–23;
Total number of MAAs per year
MRP 535 441 411 378 325 259 266 207

















































Fig. 1 Percentage of procedures
resulting in CMDh referral per
year
Table 2 Categories of ‘potential serious risk to public health’ objections raised leading to CMDh referrals and licensing failure during CMDh referrals
Main category Subcategoriesa Total, n Licensing failure, n Percent Risk ratio (95 % CI)
Clinical (study design issues) 64 21 33 % Ref
Clinical (equivalence) 64 21 33 % 1.0 (0.6–1.6)
Bioequivalence/therapeutic equivalence not demonstrated 39 15 38 % 1.2 (0.7–2.0)
Bioequivalence/therapeutic equivalence not investigated in subgroup 25 6 24 % 0.7 (0.3–1.6)
Clinical (benefit risk concerns) 83 8 10 % 0.3 (0.1–0.6)
Insufficient data to support B/R in claimed indications 34 7 21 % 0.6 (0.3–1.3)
Safety concerns 19 0 0 % NA
Overall benefit/risk negative 18 1 6 % 0.2 (0.0–1.1)
Posology concerns 12 0 0 % NA
Quality 38 3 8 % 0.2 (0.1–0.8)
Concerns on quality or manufacturing parameters 35 3 9 % 0.3 (0.1–0.8)
Packaging concerns/medication errors 3 0 0 % NA
Regulatory/procedural 40 2 5 % 0.2 (0.0–0.6)
Concerns about SmPC wording 30 1 3 % 0.1 (0.0–0.7)
Administrative concerns (including patient leaflet /SmPC issues) 10 1 10 % 0.3 (0.0–2.0)
Multiple objections from different categories 88 15 17 % 0.5 (0.3–0.9)
Overall 377 70 19 %
a For a detailed description of the categories, see supplementary information Table S2
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p<0.001). This difference remained when we limited our anal-
ysis to only MRP, or only DCP procedures. No specific time
trends were observed for the frequency of licensing failure.
Licensing failure prior to initiating a CMDh referral
In total, 16 of the 58 (28 %) invited companies returned the
survey. Of these, four companies provided two surveys from
different departments within the same company, e.g., consum-
er health care and innovative medicines, or consumer health
care and generics. This resulted in 20 completed individual
surveys, reporting a total of 208 MRP/DCP procedures
(Table 4). Out of all MRP/DCP procedures, 174 (84 %) ended
in aMA, whereas 11% resulted in licensing failure at the level
of the RMS (i.e., were refused or withdrawn) prior to CMDh
referral, and 10 (5 %) procedures were referred to the CMDh.
For 20 (10 %) of the procedures, the applicant withdrew the
application in one or moreMember States. The majority of the
withdrawals were reported to occur for reasons other than
safety concerns. Five respondents (25 %) indicated that their
company had withdrawn MAAs (and MAs) in response to
safety concerns at least once. Of all the respondents, 21 %
reported that their company had decided not to market a prod-
uct in one or more Member States because of restrictions on
the use of the product introduced during the MRP/DCP pro-
cedure at least once.
Discussion
We have provided a comprehensive overview of MAAs via
the MRP/DCP. We found that only a limited number of appli-
cations are referred to CMDh, and the majority of these refer-
rals resulted in a MA. PSRPH objections that related to the
design of the clinical studies and the demonstration of thera-
peutic equivalence and bioequivalence were most likely to
result in a licensing failure, whereas discussion on quality or
regulatory concerns rarely resulted in a licensing failure dur-
ing the procedure. Some factors, including procedure type,
legal basis and timing of the procedure were associated with
the frequency of triggering a CMDh referral, but not with a
higher rate of negative outcomes once the referral was initiat-
ed. Overall, these data show that the frequency of late-stage
licensing failure of MRP/DCP procedures, i.e., licensing fail-
ure after referral, has decreased substantially.
Care must be taken when interpreting outcomes of regula-
tory procedures. We defined licensing failure as a withdrawal
or refusal, but this does not mean that the procedure failed. On
the contrary, it may imply that the DCP/MRP functions as
expected and prevented (potential) untoward outcomes
resulting from subpar products reaching patients. Moreover,
our study focused on overall licensing failure, meaning that
we did not take into account that for some products, the
authorised indications and/or patient populations may have
been restricted at the end of the MRP/DCP procedure. Re-
spondents to the survey reported that this had on occasion
resulted in decisions not to market a product. However, we
did not systematically investigate the underlying reasons for
those restrictions. This may be a topic for further study.
The frequency of MAAs that resulted in a CMDh referral
decreased substantially over the years, indicating that reg-
ulatory learning takes place. Increased experience in the use
of this pathway may have resulted in improved MAAs filed
by companies, but also in earlier withdrawal of applications
that are likely to result in a referral. Companies may also
adapt their filing strategies to anticipate regulatory con-
cerns and file in selected Member States. For regulators,
regulatory learning means that they may have become bet-
ter in finding consensus about MAAs in earlier phases of
the application, but also the development of guidance on
what are considered PSRPHs may reduce disagreements
between different Member States [9]. Furthermore, an
ever-increasing body of information about outcomes of re-
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Fig. 2 Main categories of
‘potential serious risk to public
health’ objections per year. A
detailed overview of the category
of objection by subcategory and
licensing outcome is provided in
supplementary Table S3
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on the interpretation of PSRPHs and prevent referrals.
Work within the CMDh is ongoing to improve the
harmonised interpretation of existing guidance [14]. More-
over, ongoing harmonisation efforts of SmPCs of products
for which Member States have adopted different decisions
over the years (resulting in different authorised indications,
contraindications or posology) will continue to reduce
sources of disagreement [15].
Table 3 Other determinants of licensing failure during CMDh procedures
Category Subcategory Total Licensing failure Percent RR (95 % CI)
Procedure type DCP 135 29 21.5 % Ref
MRP 242 41 16.9 % 0.8 (0.5–1.2)
Period 2006 86 14 16.3 % Ref
2007 93 23 24.7 % 1.6 (0.9–2.8)
2008 84 11 13.1 % 0.8 (0.4–1.7)
2009 44 5 11.4 % 0.7 (0.3–1.8)
2010 15 5 33.3 % 2.1 (0.9–4.9)
2011 15 4 26.7 % 1.7 (0.6–4.4)
2012 20 2 10.0 % 0.6 (0.2–2.5)
2013 20 6 30.0 % 1.9 (0.8–4.2)
Prescription status (in RMS) Prescription only 356 65 18.3 % Ref
Non-prescription 21 5 23.8 % 1.3 (0.6–2.9)
Legal basis Art. 10.1—Generic 248 50 20.2 % Ref
Art. 8.3—Full dossier 63 4 6.3 % 0.3 (0.1–0.8)
Art. 10.3—Hybrid 29 8 27.6 % 1.4 (0.7–2.6)
Art. 10a—Well-established use (Bibliographic) 29 8 27.6 % 1.4 (0.7–2.6)
Art. 10b—Fixed combination 8 0 0.0 % NA
Active substance type Small molecules 361 68 18.8 % Ref
Biologicalsa 16 2 12.5 % 0.7 (0.2–2.5)
Route of administration Oral 264 48 18.2 % Ref
Injectables 40 4 10.0 % 0.6 (0.2–1.4)
Other systemic 30 6 20.0 % 1.8 (0.8–3.7)
Inhaled 16 5 31.3 % 1.7 (0.8–3.7)
Topical 16 3 18.8 % 1.0 (0.4–2.0)
Other 11 4 36.4 % 2.0 (0.9–4.6)
ATC level C—Cardiovascular system 88 23 26.1 % Ref
N—Nervous system 76 17 22.4 % 0.9 (0.5–1.5)
J—Anti-infectives for systemic use 38 4 10.5 % 0.4 (0.1–1.1)
A—Alimentary tract and metabolism 34 4 11.8 % 0.5 (0.2–1.2)
L—Antineoplastic and immunomodulating agents 30 1 3.3 % 0.1 (0.0–0.9)
R—Respiratory system 30 9 30.0 % 1.1 (0.6–2.2)
G—Genitourinary system and sex hormones 29 1 3.4 % 0.1 (0.0–0.9)
M—Musculoskeletal system 21 3 14.3 % 0.5 (0.2–1.7)
Other 28 5 17.9 % 0.7 (0.3–1.6)
Unknownb 3 3 100 %
RMS Other 86 22 25.6 % Ref
The Netherlands 81 4 4.9 % 0.2 (0.1–0.5)
Germany 68 9 13.2 % 0.5 (0.3–1.1)
Denmark 54 29 53.7 % 2.1 (1.4–3.2)
UK 51 6 11.8 % 0.5 (0.2–1.1)
Sweden 37 0 0.0 % NA
a Teicoplanin included in the biologics group
bAll Article 8.3 procedures (‘full dossiers’) that did not receive marketing authorisation (excluded from analysis)
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Our data clearly show that MRP procedures result in
CMDh referrals more frequently than DCP procedures. A
possible explanation for this finding is that the RMS is more
reluctant to accept changes to the existing SmPC, than in the
situation of a DCP, where there is no preexisting MA. More-
over, given the fact that DCPs do not have preexisting MAs,
companies may withdraw anMAAmore easily in response to
objections raised during the assessment procedure, in order to
resubmit with different claims, or in different member states.
Objections raised on the design and outcome of clinical
studies were most likely to lead to licensing failure. Often,
these objections related to bioequivalence parameters that
were outside predefined borders, even when the studies were
adequately designed. These cases may be the result of unfore-
seen differences in the product characteristics or due to chance
findings, which may be challenging to prevent. On the other
hand, a considerable amount of referrals were due to causes
that may have been prevented by the applicant through early
communication with the competent authorities, such as the
choice of reference product or dosage strength. Consequently,
careful planning of clinical studies and consideration of
existing guidelines could further reduce the frequency of
referrals.
We found that procedures resulting in licensing failure in-
volved fewer CMSs than those that resulted in a MA. This
seems counterintuitive, as more CMSs would give rise to
more opportunity for disagreement. A possible explanation
may be that applicants anticipate objections and file in strate-
gically selected Member States. For example, it has been
recognised that the MRP/DCP is underutilised by the non-
prescription sector, because of different approaches towards
self-medication in the member states [16]. While we did not
observe a higher frequency of licensing failure for non-
prescription medicines compared to prescription medicines,
companies may anticipate concerns during the procedure
and run multiple procedures for the same product, leading to
fewer referrals.
We found that five RMSs accounted for 78 % of all refer-
rals. However, these five countries also acted as RMSs for
69 % of all existing MAs included in the Mutual Recognition
Product Index (Table S4) [12]. ATC classes of authorised
products were also distributed unevenly over the RMSs (data
not shown), which may also account for some of the observed
variation in the licensing failure frequency seen in our study. It
may be of interest to further investigate the underlying reasons
for the observed differences in frequency of licensing failures
between RMSs.
Data from our survey suggest that 16 % of all MAAs via
the MRP/DCP procedures were withdrawn in one or all Mem-
ber States at some point. This suggests that companies antic-
ipate that objections will be raised and take mitigating
measures.
Strengths and limitations
Our study was the first to provide a comprehensive overview
of MAAs via the mutual recognition and decentralised proce-
dures. An important limitation of our study is that for the
MAAswhich did not result in a referral various attributes were
only available on an aggregated level, such as legal basis,
prescription status and procedure. While these did not show
major differences over the years, we were unable to perform
multivariate analyses to identify explanatory variables for
changes in the frequency of referrals over time. Other vari-
ables, including RMS, ATC class, and route of administration,
were unavailable altogether.
Multiple data sources were required to obtain a full picture
on the outcomes of MRP/DCP procedures. While it may be
preferable to use a single data source, the use of multiple data
sources allowed us to validate our findings. For example, it
may not be possible to extrapolate our survey results to all
users of the MRP/DCP procedures, as our sample included
only a few generic companies. Nevertheless, in our survey,
10 out of 208 procedures (4.8 %) resulted in a CMDh referral.
This is comparable to the number of referrals included in the
CMDh database (377/10,392=3.6 %), providing some reas-
surance with respect to the representativeness of the survey
sample. The data of the current study are also in accordance
with data from another study that investigated licensing failure
of DCP applications filed in the Netherlands and found that
9.8 % resulted in licensing failure (Langedijk et al., manu-
script in preparation). This is in the same range as the 7.9 %






Completed in all Member States 174 (84 %) 156 (75 %) 9 (4 %) 9 (4 %)
Withdrawn ≥1 Member Statesa 20 (10 %) 19 (9 %) 0 1 (<1 %)
Withdrawn in all Member States prior to CMDh referralb 14 (7 %) 0 14 (7 %) 0
Total number of procedures 208 (100 %) 175 (84 %) 23 (11 %) 10 (5 %)
aOutcome in remaining Member States
b Including the existing marketing authorisation in the RMS
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observed in our survey (where 7 % of the applications were
withdrawn prior to CMDh referral and an estimated 0.9 %
failed during CMDh referral).
Conclusion
A limited number of MRP/DCP procedures in our study end-
ed in a CMDh referral, and the frequency of referrals has
decreased substantially in recent years, indicating that compa-
nies and regulators have learnt to prevent late-stage failures of
MAAs via the MRP/DCP. Ever-increasing experience in
using the MRP/DCP results in a growing body of information
about past referral outcomes that may facilitate the develop-
ment of strategies to prevent licensing failure late in the pro-
cedure. Ongoing harmonisation activities on the side of regu-
latory authorities will likely lead to a further reduction of
licensing failure during the MRP/DCP procedure.
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